Medical device company Aethlon Medical Inc (Nasdaq:AEMD) reported on Tuesday the receipt of the European Patent entitled 'Extracorporeal Removal of Microvesicular Particles' for the use of the Hemopurifier technology in the treatment of cancer.
The patent, which has been assigned the No. 1,993,600 (the 600 Patent), embodies the company's Hemopurifier technology designed for the depletion of immune suppressive and potentially cancer-promoting, exosomes from the circulatory system.
According to the company, the Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections. In preclinical studies in cancer, the Hemopurifier depletes the presence of circulating tumour-derived exosomes that are believed to promote immune suppression. These tumour derived exosomes may inhibit the benefit of leading cancer therapies.
Additionally, the company has demonstrated the ability of laboratory versions of the Hemopurifier to capture exosomes underlying several forms of cancer, including breast, ovarian and melanoma, in laboratory experiments.
In November 2018, the company announced US FDA Breakthrough Device designation to support the advancement of the Hemopurifier for the treatment of cancer. In October 2019, the US FDA approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Hemopurifier in patients with advanced head and neck cancer.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial